Business
Interim Report April - June 2025
STOCKHOLM, SE / ACCESS Newswire / August 22, 2025 / Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter ...
About this update from Vicore Pharma Holding Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / August 22, 2025 / Vicore Pharma Holding AB (STO: VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for the second quarter 2025.","length":269,"tagName":"p"},{"type":"text","content":""Vicore's Phase 2b ASPIRE trial remains on track and is expected to complete enrollment in the first half of next year.","length":128,"tagName":"p"},{"type":"text","content":"During the second quarter, Vicore continued to execute with focus, ensuring efficient site activation and enrollment for the global, randomized Phase 2b ASPIRE trial. The company has a clear path forward for the development of buloxibutid in IPF and has maintained a strong financial position to allow the company to complete this impactful trial with additional cash runway thereafter."","length":392,"tagName":"p"},{"type":"text","content":"Ahmed Mousa, CEO","length":16,"tagName":"p"},{"type":"text","content":"Significant events during the second quarter","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued activation of clinical sites and enrollment of patients in the ASPIRE trial progressing as planned, remaining on track to complete enrollment in the first half of 2026.","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"In May, Vicore presented at the 2025 American Thoracic Society International Conference, showcasing new translational data demonstrating buloxibutid's unique upstream mechanism of action, a further analysis of buloxibutid's Phase 2a data in idiopathic pulmonary fibrosis (IPF) patients reflecting disease-modifying potential, and the patient-centric approaches that Vicore has taken in both the ongoing Phase 2b ASPIRE study in IPF patients and in digital health innovation.","length":482,"tagName":"p"}]},{"val":[{"type":"text","content":"Vicore participated in several investor conferences in Q2, including Jefferies Global Healthcare Conference, the Van Lanschot Kempen Life Sciences Conference, and the Nordea Equities Healthcare Seminar.","length":202,"tagName":"p"}]},{"val":[{"type":"text","content":"Successful completion of the merger between INIM Pharma AB and its parent company, Vicore Pharma Holding AB.","length":108,"tagName":"p"}]}],"tagName":...